Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Breath Analysis by Ion Mobility Spectrometry

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2011 by Lung Clinic Hemer
Information provided by:
Lung Clinic Hemer Identifier:
First received: February 29, 2008
Last updated: June 22, 2011
Last verified: May 2011

February 29, 2008
June 22, 2011
July 2006
May 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00632307 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Breath Analysis by Ion Mobility Spectrometry
Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry

Recognition of disease specific clusters of volatile organic compounds in patients with different lung diseases, using breath analysis with ion mobility spectrometry. Lung diseases of interest are:

  • COPD
  • tumors
  • airway infection
  • interstitial lung disease
  • sleep apnea Hypothesis: Breath analysis with ion mobility spectrometry can differentiate pulmonary disorders.

Recruitment of patients with different lung diseases goes on. First sub-group analysis of patients with COPD,lung cancer and sarcoidosis is done in order to create a training set of VOC-clusters for further validation in a bigger population of patients.

Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA

breath, pleural fluid (only in patients with therapeutic pleurocentesis)

Non-Probability Sample

patients of the lung clinic hemer

Lung Diseases
Not Provided
  • 1
  • 2
    lung cancer
  • 3
    airway infection
  • 4
    interstitial lung disease
  • 5
    sleep apnea
  • 6
    pulmonary disorders with pleural infusions
  • 7
  • 8
    healthy persons

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2015
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any patient
  • Ages 18-90 years old
18 Years to 90 Years
Contact: Michael Westhoff, MD 004923729082203
Contact: Patric Litterst, MD 004923729082545
Michael Westhoff MD, Lung Clinic Hemer
Lung Clinic Hemer
Not Provided
Principal Investigator: Michael Westhoff, MD Lung Clinic Hemer, 58675 Hemer, Germany
Lung Clinic Hemer
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP